

**For Immediate Release**

## **THERATECHNOLOGIES COMMENTS ON STOCK ACTIVITY**

**Montréal, January 9, 2006** – At the request of Market Regulation Services at the Toronto Stock Exchange, Theratechnologies (TSX: TH) made the following statement concerning the activity in its stock today:

“While there are no new material developments at Theratechnologies, we are aware that Geneva-based Serono S.A. announced this morning that it met all pre-specified primary and major secondary endpoints in its pivotal Phase 3 double-blind, placebo-controlled trial of its recombinant human growth hormone in the treatment of HIV-associated Adipose Redistribution Syndrome (HARS). Investors may have been encouraged by this announcement because Theratechnologies is presently recruiting patients in a Phase 3 clinical trial for a similar indication testing its growth hormone releasing factor analogue, TH9507, with results expected in the fourth quarter of 2006”.

### **About Theratechnologies**

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets where it can retain full or partial commercial rights for its products. Its most advanced program is TH9507, now in Phase 3 clinical trials for a serious metabolic syndrome known as HIV-associated lipodystrophy. The Company also has other promising projects at earlier stages of development.

### **Additional information about Theratechnologies**

Further information relating to Theratechnologies is available on the Company's website at <http://www.theratech.com/>. The Company is listed on the Toronto Stock Exchange under the symbol TH. Additional information, including the Company's Annual Information Form, is available on SEDAR at [www.sedar.com](http://www.sedar.com).

*This press release contains forward-looking statements regarding the timing of the clinical development of TH9507. Such statements inherently involve numerous risks and uncertainties, including the availability of funds and resources and the success and timely completion of clinical trials. Actual future results may differ materially from the anticipated results. Investors are cautioned against placing undue importance on forward-looking information contained herein and should consult the Company's 2004 Annual Report, which contains a more exhaustive analysis of risks and uncertainties connected to the businesses of the Company.*

### **To obtain additional information, contact:**

Yves Rosconi  
President and Chief Executive Officer  
Phone: 514-336-4804, ext. 221  
[yrosconi@theratech.com](mailto:yrosconi@theratech.com)

Peter McBride  
Vice President, Investor Relations and  
Public Affairs  
Phone: 514-336-4804, ext. 215  
[pmcbride@theratech.com](mailto:pmcbride@theratech.com)

### **Theratechnologies Inc.**

2310 Alfred-Nobel Blvd., Saint Laurent, Québec, Canada H4S 2A4  
Phone: (514) 336-7800 • Fax: (514) 336-7242 • [www.theratech.com](http://www.theratech.com) • [thera@theratech.com](mailto:thera@theratech.com)

